This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): ranibizumab, rhuFab V2, AMD-fab, RG3645
Description: Lucentis is the antigen-binding fragment of a humanized anti-VEGF antibody. VEGF activity is critical to the growth of blood vessels that occurs in age-related macular degeneration (AMD).
Revenue splits for this drug are BioMedTracker estimates.
Genentech and Novartis
Genentech and Novartis partnered in June 2003 to develop Lucentis. Novartis Ophthalmics will market the drug outside of North America for eye disorder related indications. Genentech will receive royalties for sales outside North America, and will market the drug in the U.S., Canada, and Mexico.
Lucentis and XOMA
Lucentis was created using the license of XOMA's Bacterial Cell Expression (BCE) technology. XOMA will receive a royalty on worldwide sales of Lucentis.
Roche and Genentech
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
PDLI and...See full deal structure in Biomedtracker
Partners: Novartis AG PDL BioPharma, Inc. XOMA Corporation ForSight VISION4, Inc.
Additional information available to subscribers only: